Capital Investment Advisors Position in Apple Computer (AAPL) Trimmed by $894,375; Carmignac Gestion Upped Chemocentryx (CCXI) Position by $3.30 Million

Apple Inc. (NASDAQ:AAPL) Logo

Carmignac Gestion increased its stake in Chemocentryx Inc (CCXI) by 26.83% based on its latest 2018Q3 regulatory filing with the SEC. Carmignac Gestion bought 275,273 shares as the company’s stock declined 9.75% with the market. The institutional investor held 1.30 million shares of the health care company at the end of 2018Q3, valued at $16.45M, up from 1.03M at the end of the previous reported quarter. Carmignac Gestion who had been investing in Chemocentryx Inc for a number of months, seems to be bullish on the $543.66M market cap company. The stock decreased 0.74% or $0.08 during the last trading session, reaching $10.76. About 106,350 shares traded. ChemoCentryx, Inc. (NASDAQ:CCXI) has risen 69.59% since February 28, 2018 and is uptrending. It has outperformed by 69.59% the S&P500. Some Historical CCXI News: 13/03/2018 – CHEMOCENTRYX INC CCXI.O : JP MORGAN RAISES TARGET PRICE TO $16 FROM $13; 11/04/2018 – ChemoCentryx Announces Presentation During National Kidney Foundation 2018 Spring Clinical Meeting; 09/03/2018 – ChemoCentryx Expects to Utilize Between $65M-$75M Cash and Investments in FY18; 09/03/2018 – ChemoCentryx 4Q Net $39.7M; 03/04/2018 – ChemoCentryx Presenting at Conference Apr 9; 09/03/2018 ChemoCentryx 4Q EPS 80c; 09/05/2018 – ChemoCentryx 1Q Loss/Shr 19c; 09/03/2018 – CHEMOCENTRYX SEES 2018 CASH & INVESTMENTS USE $65M-$75M; 09/03/2018 – CCXI TO BEGIN AVACOPAN CLINICAL STUDIES IN HS BY ’18 END; 09/03/2018 – ChemoCentryx Intends to Initiate Clinical Development of Avacopan in Hidradenitis Suppurativa by Yr-En

Capital Investment Advisors Llc decreased its stake in Apple Computer Inc (AAPL) by 4.5% based on its latest 2018Q3 regulatory filing with the SEC. Capital Investment Advisors Llc sold 3,975 shares as the company’s stock declined 22.32% with the market. The institutional investor held 84,373 shares of the computer manufacturing company at the end of 2018Q3, valued at $19.05M, down from 88,348 at the end of the previous reported quarter. Capital Investment Advisors Llc who had been investing in Apple Computer Inc for a number of months, seems to be less bullish one the $821.45 billion market cap company. The stock decreased 0.38% or $0.66 during the last trading session, reaching $174.21. About 13.16 million shares traded. Apple Inc. (NASDAQ:AAPL) has risen 0.17% since February 28, 2018 and is uptrending. It has outperformed by 0.17% the S&P500. Some Historical AAPL News: 01/05/2018 – APPLE’S OUTLOOK REMAIN UNCHANGED AT STABLE BY MOODY’S; 09/05/2018 – Alphabet, Apple and Microsoft will be part of government drone pilots, but Amazon was left out; 29/03/2018 – Apple announced on Thursday that it has expanded its health records product to 40 health systems and 300 hospitals, and it’s opening it up to all iOS users; 23/04/2018 – Apple’s Deal for Shazam Is Delayed in Europe Over Data Concerns; 23/03/2018 – Apple reportedly unveiling a cheaper iPad next week. via @verge; 07/03/2018 – Ireland chooses BNY Mellon to manage Apple escrow fund; 29/05/2018 – Pegatron ships prototype MacBooks powered by Apple processors, supply chain sources say; 27/04/2018 – Tesla’s head of Autopilot leaves; ex-Apple exec to succeed him; 23/05/2018 – Apple, Spurned by BMW and Mercedes, Signs Deal With Volkswagen for Driverless Cars; 12/03/2018 – Apple to Acquire Magazine-Subscription Service Texture–Update

Capital Investment Advisors Llc, which manages about $1.70 billion US Long portfolio, upped its stake in A T & T Corp (NYSE:T) by 41,697 shares to 520,355 shares, valued at $17.47 million in 2018Q3, according to the filing. It also increased its holding in Simon Ppty Group New (NYSE:SPG) by 9,394 shares in the quarter, for a total of 47,672 shares, and has risen its stake in Abbvie (NYSE:ABBV).

More notable recent Apple Inc. (NASDAQ:AAPL) news were published by: Seekingalpha.com which released: “Apple: Stress-Valuation – Seeking Alpha” on February 25, 2019, also Seekingalpha.com with their article: “Apple: Comparable Valuation That Will Surprise You – Seeking Alpha” published on February 13, 2019, Seekingalpha.com published: “Apple’s Q4 HomePod shipments grew 45% – Seeking Alpha” on February 19, 2019. More interesting news about Apple Inc. (NASDAQ:AAPL) were released by: Nasdaq.com and their article: “After Hours Most Active for Feb 27, 2019 : BABA, GE, ZNGA, SYF, WFC, BAC, V, MSFT, XOG, MU, FEYE, AAPL – Nasdaq” published on February 27, 2019 as well as Seekingalpha.com‘s news article titled: “Apple’s Transformation Is Underway – Seeking Alpha” with publication date: February 27, 2019.

Investors sentiment decreased to 0.67 in Q3 2018. Its down 0.04, from 0.71 in 2018Q2. It dropped, as 54 investors sold AAPL shares while 1030 reduced holdings. 151 funds opened positions while 577 raised stakes. 2.68 billion shares or 3.22% less from 2.77 billion shares in 2018Q2 were reported. Advisor Partners Ltd Liability owns 4.13% invested in Apple Inc. (NASDAQ:AAPL) for 135,762 shares. David R Rahn Assoc has 15,533 shares for 3.2% of their portfolio. Mariner Wealth Advsrs holds 1.51% of its portfolio in Apple Inc. (NASDAQ:AAPL) for 121,394 shares. Natl Registered Inv Advisor holds 34,673 shares or 4.11% of its portfolio. Mckinley Carter Wealth Serv accumulated 38,506 shares or 2.58% of the stock. Ensemble Cap Mgmt Limited Com has 3.44% invested in Apple Inc. (NASDAQ:AAPL) for 92,575 shares. Bokf Na owns 403,099 shares for 2.28% of their portfolio. 10,700 are held by Tributary Capital Mngmt Ltd Liability Co. Checchi Advisers Ltd Liability Com invested in 65,817 shares or 1.71% of the stock. Inv Counsel reported 177,006 shares or 14.68% of all its holdings. Miller Management LP reported 10,534 shares. 28,544 are owned by Zevin Asset Management Ltd Liability Corporation. Phocas Corporation holds 0.17% in Apple Inc. (NASDAQ:AAPL) or 8,417 shares. Waratah Capital Advsr Ltd has 0.06% invested in Apple Inc. (NASDAQ:AAPL). Ls Invest Advsrs Lc accumulated 233,173 shares.

Since November 19, 2018, it had 0 insider buys, and 2 sales for $902,607 activity. KONDO CHRIS had sold 3,408 shares worth $647,520.

Since October 16, 2018, it had 0 buys, and 8 sales for $87.64 million activity. Another trade for 30,237 shares valued at $332,779 was sold by Cappel Markus J.. $85.85M worth of ChemoCentryx, Inc. (NASDAQ:CCXI) was sold by GLAXOSMITHKLINE PLC. KANAYA SUSAN M sold $457,747 worth of ChemoCentryx, Inc. (NASDAQ:CCXI) on Tuesday, January 22.

Investors sentiment decreased to 0.98 in Q3 2018. Its down 0.61, from 1.59 in 2018Q2. It worsened, as 14 investors sold CCXI shares while 29 reduced holdings. 13 funds opened positions while 29 raised stakes. 26.80 million shares or 1.64% more from 26.37 million shares in 2018Q2 were reported. Bnp Paribas Arbitrage has 738 shares for 0% of their portfolio. 26,447 were reported by Smith Asset Management Grp L P. Farallon Capital Limited Co owns 1.15M shares for 0.09% of their portfolio. Bank Of America Corporation De holds 0% of its portfolio in ChemoCentryx, Inc. (NASDAQ:CCXI) for 101,800 shares. Barclays Pcl holds 0% or 15,304 shares in its portfolio. 1.45 million are held by Franklin. Tower Capital Limited Liability (Trc) owns 0% invested in ChemoCentryx, Inc. (NASDAQ:CCXI) for 626 shares. Proshare Advsr Limited Liability holds 0% in ChemoCentryx, Inc. (NASDAQ:CCXI) or 23,294 shares. Germany-based Deutsche State Bank Ag has invested 0% in ChemoCentryx, Inc. (NASDAQ:CCXI). Federated Invsts Inc Pa owns 65,761 shares or 0% of their US portfolio. Morgan Stanley has invested 0% in ChemoCentryx, Inc. (NASDAQ:CCXI). Jpmorgan Chase Commerce reported 5,203 shares stake. J Goldman & LP invested in 0.03% or 32,500 shares. State Street has 0% invested in ChemoCentryx, Inc. (NASDAQ:CCXI). Sei Invests invested in 67,062 shares.

Apple Inc. (NASDAQ:AAPL) Institutional Positions Chart

Source link

Peoples Financial Services Has Boosted Its Phillips 66 (PSX) Stake; Inflarx N.V. (IFRX) SI Decreased By 1.57%

Phillips 66 (NYSE:PSX) Logo

Inflarx N.V. (NASDAQ:IFRX) had a decrease of 1.57% in short interest. IFRX’s SI was 231,600 shares in February as released by FINRA. Its down 1.57% from 235,300 shares previously. With 11,900 avg volume, 20 days are for Inflarx N.V. (NASDAQ:IFRX)’s short sellers to cover IFRX’s short positions. The SI to Inflarx N.V.’s float is 3.2%. The stock increased 5.81% or $1.91 during the last trading session, reaching $34.81. About 90,681 shares traded or 1.53% up from the average. InflaRx N.V. (NASDAQ:IFRX) has risen 63.49% since February 28, 2018 and is uptrending. It has outperformed by 63.49% the S&P500. Some Historical IFRX News: 08/05/2018 – InflaRx N.V. Announces Closing of Primary and Secondary Offering of Common Shrs; 17/05/2018 – InflaRx 1Q Loss/Shr EUR0.04; 03/05/2018 – INFLARX PRIMARY, SECONDARY OFFERINGS PRICES AT $34.00 PER SHARE; 29/03/2018 – lnflaRx Full Year 2017 Financial & Operating Results; 08/03/2018 InflaRx announces first patient enrolled in Phase IIb trial with lead candidate IFX-1 in Hidradenitis Suppurativa; 08/03/2018 – INFLARX ANNOUNCES FIRST PATIENT ENROLLED IN PHASE llB TRIAL WITH LEAD CANDIDATE IFX-1 IN HIDRADENITIS SUPPURATIVA; 29/03/2018 – InflaRx FY Loss/Shr EUR2.6; 17/05/2018 – INFLARX NV – CASH POSITION APPROXIMATELY US$137 MLN (EUR 115 MLN) AS OF MARCH 31, 2018; 08/03/2018 – lnflaRx announces first patient enrolled in Phase llb trial with lead candidate IFX-1 in Hidradenitis Suppurativa; 29/03/2018 – InflaRx Full Year 2017 Financial & Operating Results

Peoples Financial Services Corp increased Phillips 66 (PSX) stake by 50.71% reported in 2018Q3 SEC filing. Peoples Financial Services Corp acquired 3,360 shares as Phillips 66 (PSX)’s stock declined 22.04%. The Peoples Financial Services Corp holds 9,986 shares with $1.13 million value, up from 6,626 last quarter. Phillips 66 now has $44.52 billion valuation. The stock decreased 0.20% or $0.2 during the last trading session, reaching $97.64. About 1.88M shares traded. Phillips 66 (NYSE:PSX) has declined 9.22% since February 28, 2018 and is downtrending. It has underperformed by 9.22% the S&P500. Some Historical PSX News: 08/03/2018 – PHILLIPS 66 ALLIANCE LOUISIANA REFINERY BEGINS REFORMER, HYDROTREATER OVERHAUL; 26/04/2018 – Skinny and sweet: U.S. refiner earnings depend on the oil diet; 25/04/2018 – Phillips 66 expected to post earnings of 89 cents a share – Earnings Preview; 27/04/2018 – Phillips 66 1Q EPS $1.07; 05/05/2018 – Praise for Phillips 66 — Berkshire Hathaway Annual Meeting; 17/04/2018 – Phillips 66’s JV Borger, Texas gasoline units due back next week; 27/04/2018 – PHILLIPS 66 QTRLY TOTAL REVENUES AND OTHER INCOME $24,046 MLN VS $23,712 MLN; 16/05/2018 – Phillips 66 Presenting at Conference Tomorrow; 27/04/2018 – Phillips 66 1Q Operating Cash Flow $488 Million; 17/04/2018 – Phillips 66 Reports Equipment Issues at Sweeny Refinery in Texas

More notable recent InflaRx N.V. (NASDAQ:IFRX) news were published by: Nasdaq.com which released: “InflaRx Receives Approval to Initiate Phase IIa Clinical Trial with Lead Candidate IFX-1 in Pyoderma Gangraenosum – Nasdaq” on February 27, 2019, also Globenewswire.com with their article: “Richard Brudnick to Join InflaRx Board of Directors – GlobeNewswire” published on February 14, 2019, Globenewswire.com published: “Market Trends Toward New Normal in Nuance Communications, Fate Therapeutics, Hamilton Lane, InflaRx NV, Enerplus, and ManTech International — Emerging Consolidated Expectations, Analyst Ratings – GlobeNewswire” on February 25, 2019. More interesting news about InflaRx N.V. (NASDAQ:IFRX) were released by: Nasdaq.com and their article: “Dassault Aviation: Financial Release – 2018 annual results – Nasdaq” published on February 28, 2019 as well as Nasdaq.com‘s news article titled: “Biocartis Group NV: BIOCARTIS ANNOUNCES 2018 RESULTS AND 2019 OUTLOOK – Nasdaq” with publication date: February 28, 2019.

InflaRx GmbH, a clinical-stage biopharmaceutical company, focuses on discovering and developing inhibitors using C5a technology in the United States. The company has market cap of $893.30 million. The Company’s C5a is an inflammatory mediator involved in the enhancement of a variety of autoimmune and other inflammatory diseases. It currently has negative earnings. The firm is involved developing IFX-1, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and other chronic/autoimmune diseases, as well as IFX-2 for the treatment of chronic inflammation and autoimmune diseases.

Among 9 analysts covering Phillips 66 (NYSE:PSX), 6 have Buy rating, 0 Sell and 3 Hold. Therefore 67% are positive. Phillips 66 had 11 analyst reports since September 7, 2018 according to SRatingsIntel. The firm has “Equal-Weight” rating by Morgan Stanley given on Tuesday, November 20. The firm has “Buy” rating given on Thursday, December 20 by Jefferies. The company was upgraded on Friday, November 16 by U.S. Capital Advisors. The firm has “Overweight” rating given on Thursday, January 10 by PiperJaffray. The firm has “Overweight” rating by JP Morgan given on Tuesday, October 30. Barclays Capital upgraded it to “Equal-Weight” rating and $128 target in Wednesday, October 3 report. The rating was maintained by Wells Fargo with “Outperform” on Monday, October 29. Raymond James maintained Phillips 66 (NYSE:PSX) rating on Monday, October 29. Raymond James has “Outperform” rating and $135 target. Raymond James maintained Phillips 66 (NYSE:PSX) on Monday, December 31 with “Outperform” rating. The rating was maintained by Citigroup on Friday, September 7 with “Neutral”.

Investors sentiment increased to 1.19 in 2018 Q3. Its up 0.03, from 1.16 in 2018Q2. It is positive, as 35 investors sold PSX shares while 356 reduced holdings. 113 funds opened positions while 351 raised stakes. 305.42 million shares or 2.74% less from 314.02 million shares in 2018Q2 were reported. Price T Rowe Inc Md has 0.08% invested in Phillips 66 (NYSE:PSX). 161,913 are owned by Todd Asset Mngmt Lc. Williams Jones & Associate Limited Liability Corp accumulated 3,489 shares. Checchi Advisers Ltd Com has 5,194 shares for 0.07% of their portfolio. Bridges Mgmt Incorporated invested in 0.01% or 2,250 shares. Moreover, Of Vermont has 0.03% invested in Phillips 66 (NYSE:PSX) for 3,520 shares. Fire Grp accumulated 5,029 shares. First Personal holds 0.05% of its portfolio in Phillips 66 (NYSE:PSX) for 1,357 shares. Massachusetts-based Eastern Financial Bank has invested 0.02% in Phillips 66 (NYSE:PSX). United Automobile Association owns 0.15% invested in Phillips 66 (NYSE:PSX) for 530,164 shares. Eqis Cap Mngmt holds 0.09% or 12,405 shares in its portfolio. Navellier And Assoc Inc stated it has 41,613 shares or 0.61% of all its holdings. 458 were reported by Fincl Engines Advsrs Ltd Liability Corporation. Korea Inv owns 206,523 shares. 11,061 are held by Cleararc Capital.

More notable recent Phillips 66 (NYSE:PSX) news were published by: Seekingalpha.com which released: “Phillips 66: An Extraordinary Energy Logistics Company – Seeking Alpha” on February 27, 2019, also Seekingalpha.com with their article: “Phillips 66: Another Success Story Among Refiners – Seeking Alpha” published on February 28, 2019, Seekingalpha.com published: “Phillips 66 Is On My Watchlist – Seeking Alpha” on February 11, 2019. More interesting news about Phillips 66 (NYSE:PSX) were released by: Seekingalpha.com and their article: “Phillips 66 Posts Stellar 2018 Performance But Tricky Road Ahead – Seeking Alpha” published on February 10, 2019 as well as Globenewswire.com‘s news article titled: “New Research: Key Drivers of Growth for Phillips 66, Seattle Genetics, Green Plains, C&J Energy Services, FRP, and Medical Transcription Billing — Factors of Influence, Major Initiatives and Sustained Production – GlobeNewswire” with publication date: February 13, 2019.

Since November 20, 2018, it had 1 insider buy, and 0 insider sales for $1.98 million activity. The insider FERGUSON J BRIAN bought 21,500 shares worth $1.98 million.

Phillips 66 (NYSE:PSX) Institutional Positions Chart


Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.



Source link

Target PharmaSolutions & Novartis to launch real-world dermatology study

Target PharmaSolutions has named Novartis as its first industry partner to provide multi-year support to the company’s TARGET-DERM registry.

TARGET-DERM is a global longitudinal observational study that evaluates adult and pediatric patients with immune-mediated inflammatory skin conditions (IMISCs).

The study will initially focus on patients with eczema and will expand to include other skin conditions, including hidradenitis suppurativa – painful bumps under the skin, alopecia areata – autoimmune-related hair loss, and vitiligo and will be led by an academic steering committee chaired by Emma Guttman-Yassky, The Sol and Clara Kest Professor of Dermatology and Immunology.

“We are very excited for Novartis to join as the first industry partner in TARGET-DERM,” said Meg Powell, chair of the board of Target PharmaSolutions.

“We have received strong interest from many stakeholders in the dermatology community regarding the need for high-quality, longitudinal, real-world data on patients with eczema and other inflammatory skin conditions related to immune response.

Real-world data gathered from TARGET-DERM will be a valuable resource for our collaborators as they work to better understand and to combat these complex skin diseases, and could have life-altering implications for the millions of people around the world who suffer from them.”

TARGET-DERM is the sixth disease category spearheaded by Target PharmaSolutions since 2015, whose ongoing real-world studies include nonalcoholic steatohepatitis (NASH), hepatocellular carcinoma (HCC), inflammatory bowel disease (IBD), primary biliary cholangitis (PBC) and chronic hepatitis B (HBV).

Source link

Latest Valuation: InflaRx N.V. (NASDAQ: IFRX)

GSSSB Senior Clerk Answer Key

The long-term trend of the EPS is a vital number as it helps understand the future potential of InflaRx N.V.;

InflaRx N.V. is in the healthcare sector and is part of the biotechnology industry. The company CEO is Niels Riedemann. InflaRx NV is a biopharmaceutical company. It discovers and develops potent and specific inhibitors of the complement activation factor known as C5a.

Previous Intraday Performance:

The IFRX shares had a previous change of 0.31% which opened at 32.94 and closed at 32.90. It moved to an intraday high of 34.12 and a low of 32.39.

SeekingAlpha:  XBiotech: Strong Upside Potential In Atopic Dermatitis And Hidradenitis Suppurativa

Historical Performance:

Over the last five trading days, IFRX shares returned 0.37% and in the past 30 trading days it returned -2.84%. Over three months, it changed 24.86%. In one year it has changed 4.78% and within that year its 52-week high was 42.83 and its 52-week low was 20.31. IFRX stock is 61.99% above its 52 Week Low.

Our calculations result in a 200 day moving average of 32.58 and a 50 day moving average of 32.33. Right now, IFRX stock is trading 0.97% above its 200 day moving average and may be a good opportunity to buy.

SeekingAlpha:  XBiotech: Strong Upside Potential In Atopic Dermatitis And Hidradenitis Suppurativa

Liquidity:

The company has a market cap of $853.3m with 25.9m shares outstanding and a float of 25.9m shares. Trading volume was 62,186 shares and has experienced an average volume of 102,037 shares. Our calculation, using the current average volume and close price, leads me to believe that the liquidity is bad, highly speculative and an investor may want to avoid this stock.

Earnings:

The last annual reported EPS for InflaRx N.V. was -3.12 which ended on 31st of December 2017. Based on 5 analyst estimates, the consensus EPS for the next quarter is -0.44.

Below was the last reported quarterly earnings per share:
09-30-2018:  -0.31
06-30-2018:  -0.12
03-31-2018:  -0.49

Indicators Also to Watch:

Based on the latest filings, there is 58.20% of institutional ownership.

I calculated the beta to be -0.95

SeekingAlpha:  Malibu Boats, Inc. 2019 Q2 – Results – Earnings Call Slides

Fundamental Numbers:

Based on last reported financials, the company’s return on equity is -51.21%, return on assets is -33.08% and price-to-book is 4.62.

Company Score Card:

Results are out of six:
 0  : Growth Expectations Result
 6  : Financial Safety Result
 0  : Past Performance Result
 0  : Valuation Result
 0  : Dividend Safety Result
 1  : Overall Result

Related
Tags: , , ,

Source link

TARGET PharmaSolutions® to Advance Dermatology Research, including Atopic Dermatitis, through New Collaboration

DURHAM, N.C., Feb. 27, 2019 /PRNewswire/ — TARGET PharmaSolutions, Inc., a real-world clinical data solutions company, is pleased to announce that Novartis Pharma AG is the first industry partner to provide multi-year support to TARGET-DERM registry. TARGET-DERM is a global longitudinal observational study that evaluates adult and pediatric patients with immune-mediated inflammatory skin conditions (IMISCs). 

TARGET-DERM will initially focus on patients with atopic dermatitis (eczema) and will expand to include other skin conditions, including hidradenitis suppurativa (painful bumps under the skin), alopecia areata (autoimmune-related hair loss), and vitiligo (loss of skin pigment).  These chronic inflammatory skin disorders constitute a substantial financial burden on the US health care system, and are among the greatest contributors to the burden of skin disease worldwide.  Currently enrolling, the study is led by an academic steering committee chaired by Emma Guttman-Yassky, MD, PhD, The Sol and Clara Kest Professor of Dermatology and Immunology, and Vice Chair, department of Dermatology, The Icahn School of Medicine at Mount Sinai, New York, and Diamant Thaçi, MD, PhD, Professor and Head, Comprehensive Center for Inflammation Medicine, University of Lubeck, Germany.

“This partnership confirms Novartis’ commitment to immuno-dermatology. Better understanding of diseases such as atopic dermatitis can help bring forward innovation that can be transformative for patients, their families and health care systems,” said Eric Hughes, Development Unit Head, Immunology, Hepatology and Dermatology.

“We are very excited for Novartis to join as the first industry partner in TARGET-DERM,” said Meg Powell, PharmD, Chair of the Board of TARGET PharmaSolutions. “We have received strong interest from many stakeholders in the dermatology community regarding the need for high-quality, longitudinal, real-world data on patients with eczema and other inflammatory skin conditions related to immune response.  Real-world data gathered from TARGET-DERM will be a valuable resource for our collaborators as they work to better understand and to combat these complex skin diseases, and could have life-altering implications for the millions of people around the world who suffer from them.” 

TARGET-DERM is the sixth disease category spearheaded by TARGET PharmaSolutions since 2015. Ongoing real-world TARGET studies include nonalcoholic steatohepatitis (NASH), hepatocellular carcinoma (HCC), inflammatory bowel disease (IBD), primary biliary cholangitis (PBC) and chronic hepatitis B (HBV).

The TARGET model organizes a community of stakeholders, including key scientific leaders, regulatory agencies, pharmaceutical manufacturers, and patient advocacy groups, around a specific disease to generate real world evidence about the natural history of the given disease, current treatment paradigm, and patient outcomes.  This model enables TARGET’s stakeholders to answer critical strategic and planning questions.  TARGET PharmaSolutions also provides regulatory grade data and analysis that may be used throughout the pharmaceutical development and commercialization process, including expanded indications and fulfillment of post-market studies. 

Novartis is a global healthcare company that provides innovative healthcare solutions that address the evolving needs of patients and societies. Immuno-dermatology, including atopic dermatitis portfolio, is one of the key therapeutic areas of research and development for Novartis.

About TARGET PharmaSolutions

Headquartered in Durham, NC, TARGET PharmaSolutions is a privately held data solutions company that provides pharmaceutical and biotechnology partners a more efficient way to generate and analyze data in the real-world setting.  For more information, visit www.targetpharmasolutions.com.

CONTACT:
Matt Casbon
TARGET PharmaSolutions, Inc.
mcasbon@targetpharmasolutions.com
984.234.0268

SOURCE TARGET PharmaSolutions, Inc.

Related Links

http://www.targetpharmasolutions.com

Source link

McGill Dermatology graduate becomes first Canadian to receive prestigious international medical award : Med e-News

Live 2019

L to R: Prof. Christos C. Zouboulis, Prof. Jacek C. Szepietowski, Prof. Wayne Gulliver, Prof. Lukasz Matusiak, Prof. Ximena Wortsman, Prof. Gregor B.E. Jemec.

Dr. Wayne Gulliver, who graduated from McGill University’s Dermatology program in 1989, was recently presented the Albert Neisser Lecture at the Wroclaw Opera House during the 8th European Hidradenitis Suppurativa Foundation Conference, February 6, 2019 in Warsaw, Poland. He is the first Canadian to receive this award.

The Albert Neisser Lectureship is awarded to dermatologists who have made significant clinical and research contributions to dermatology.  Dr. Gulliver who is professor of Medicine and Dermatology, Memorial University of Newfoundland & Labrador was honoured for his pioneering work in the use of biologics in the treatment of hidradenitis suppurativa and his landmark publication on evidence-based therapy in the treatment of hidradenitis suppurativa.

The Albert Neisser Lectureship has been awarded since 2005 and is given to honour Prof. Dr. Albert Neisser who was appointed professor extraordinarius by the University of Wroclaw Medical School at the age of 29, in 1882.  Dr. Neisser’s accomplishments include his work on discovering the pathogen of leprosy as well as STDs.  He was also active in the field of public health and clinical research. Some notable recipients include Prof. Dr. Andrew Y. Finlay, Cardiff, UK and Prof. Dr. med. Dr. h.c. Thomas Ruzicka, Munich, Germany.

Dr. Wayne Gulliver is a Dermatologist experienced as a clinician, educator, administrator, clinical and basic science researcher.  He has been in clinical practice for nearly 30 years and has supervised over 250 clinical trials covering many aspects of dermatology with the focus in genetics, psoriasis, wound care, virology and hidradenitis suppurativa.  He has more than 100 published papers authored or co-authored, as well as more than 200 abstracts authored or co-authored.

Other Notable Awards Received:

  • the Wyeth Award for Excellence in Research, McGill University, Montreal in 1989
  • the BioEast Entrepreneurship Award in 2001
  • the Newfoundland & Labrador and Labrador Association of Technology Industries (NATI) Life Sciences – Biotechnology Industry Award in 2005
  • the JD Eaton Alumni Award, Memorial University, recognizing exceptional leadership and outstanding service to Memorial in 2007, and
  • was inducted into the Canadian Healthcare Marketing Hall of Fame in 2015

Other Career Highlights:

  • Former chair of the Discipline of Medicine, Memorial University of Newfoundland & Labrador (2009 – 2011)
  • Professor of Medicine and Dermatology as well as Head of Dermatology, Faculty of Medicine, Memorial University of Newfoundland & Labrador (1989 – present)
  • Adjunct Professor, Henan University of Traditional Chinese Medicine, and Zhengzhou University, Henan, PR China
  • Chair and Medical Director of NewLab Clinical Research Inc. (1996-2009)
  • Chief Scientific Officer, NewLab Life Sciences (2009 – 2011)
  • Vice-President of the Canadian Dermatology Association (1996-1997)
  • Former Chief, Division of Dermatology, Eastern Health, St. John’s, Newfoundland & Labrador (1996–2008)
  • Co-founder Newfound Genomics
  • Former member of the Governing Council of the National Research Council (2003-2006)
  • Member of the Editorial Board for the Journal of Cutaneous Medicine and Surgery and Medical Editor The Chronicle of Skin & Allergy.
  • Editor The Chronicle of Skin & Allergy
  • Chair, Newfoundland & Labrador and Labrador Association of Technology Industries (NATI) (2008-2009)

Congratulations Dr. Gulliver!

February 27, 2019

Source link

Hidradenitis Suppurativa Market 2018 to 2023 Future Demand Analysis, Industry sizes, Share, opportunity and Market overviews

Premium Research Report on Hidradenitis Suppurativa Market made available by Worldwide Market Reports 2018 – 2023 offering latest Industry review, Regional market, Opportunities, Emerging growth factor, Drivers, challenges, Characterization, application, innovation, openings, future guide, and most recent market competitors joined with their market share. The report covers a thorough perception of the Hidradenitis Suppurativa market and identifies the key trends associated with the different sectors of the market.

This Hidradenitis Suppurativa market report focuses on Value Chain Analysis and exhaustive Market information about the Top Manufacture with future plans and financial performance. In this report, the study covers Recent Developments, Updates in Key players, Market regulation and market trends. We also give the details solution about the business trends, latest geographical market segmentation, and market challenges. On the basis of Consumers Analysis, gross margin analysis, distribution analysis, and local consumption analysis it’s will help to grow your business on the top across the world.

Get PDF Sample Copy of This Report: @ https://www.worldwidemarketreports.com/sample/179309

The report also provides a competitor analysis of Key Trends & advanced technologies. The Hidradenitis Suppurativa (Thousands Units) and Revenue (Million USD) Market Split by Key players such as Company A, Company B, Company C… Continued.

The Hidradenitis Suppurativa Market coverage of this report includes:

  1. It helps every manufacturer with respect to the company profile, a generic overview, and the products offered have also been given.
  2. The report developed on product sales, revenue increase, price patterns, and gross margins.
  3. The Data will help with respect to the most recent news that each organization is involved in has been providing in the observation study.
  4. Its provide details Analysis of the pivotal competitors and their future opportunities in the industry.
  5. The report explains on the item deals, income gathered, value examples, and gross margin.

Major Regions covers:

Geographically, this report split global into several key Regions, with sales (MT), revenue (Million USD), and market share and growth rate of Hidradenitis Suppurativa for these regions, covering

North America (USA, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India, and Southeast Asia)
South America (Brazil, Argentina, Columbia etc.)
The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, and South Africa)

The Hidradenitis Suppurativa market report includes the finding the detailed study of competitive analysis of the industry of the industry. The Hidradenitis Suppurativa market reports also give key developments strategies and policies along with manufacturing strategy. The Hidradenitis Suppurativa reports a cover the exact study of the key players to figure out their business strategies, annual revenue, company profile and their allotment to the global Hidradenitis Suppurativa market share. The key detail of the Hidradenitis Suppurativa industry such as the supply chain analysis.

Have Any Query? Ask Our Expert at @ https://www.worldwidemarketreports.com/quiry/179309

About Worldwide Market Reports:

Worldwide Market Reports is your one-stop repository of detailed and in-depth market research reports compiled by an extensive list of publishers from across the globe. We offer reports across virtually all domains and an exhaustive list of sub-domains under the sun. WMR well-researched inputs that encompass domains enable our prized clients to capitalize upon key growth opportunities and shield against credible threats prevalent in the market in the current scenario and those expected in the near future.

Source link

Inflarx (IFRX) Price Target Raised to $65.00 at JPMorgan Chase & Co.

Inflarx (NASDAQ:IFRX) had its price objective upped by analysts at JPMorgan Chase & Co. from $42.00 to $65.00 in a research note issued on Tuesday, February 5th, The Fly reports. The brokerage presently has a “top pick” rating on the stock. JPMorgan Chase & Co.‘s price objective points to a potential upside of 86.73% from the company’s previous close.

Several other equities analysts have also weighed in on IFRX. Zacks Investment Research lowered Inflarx from a “buy” rating to a “hold” rating in a report on Wednesday, January 30th. ValuEngine raised Inflarx from a “hold” rating to a “buy” rating in a report on Monday, February 4th. Credit Suisse Group assumed coverage on Inflarx in a report on Monday, December 10th. They set an “outperform” rating and a $47.00 price objective for the company. Finally, Robert W. Baird started coverage on Inflarx in a report on Monday, January 28th. They set an “outperform” rating and a $62.00 price objective for the company. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. Inflarx presently has a consensus rating of “Buy” and an average target price of $51.67.

Shares of Inflarx stock traded up $1.91 on Tuesday, hitting $34.81. The company had a trading volume of 90,600 shares, compared to its average volume of 87,156. The company has a market cap of $784.24 million, a PE ratio of -11.84 and a beta of -0.94. Inflarx has a 1 year low of $20.31 and a 1 year high of $42.83.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in IFRX. Millennium Management LLC increased its holdings in shares of Inflarx by 18.1% in the fourth quarter. Millennium Management LLC now owns 72,153 shares of the company’s stock worth $2,624,000 after buying an additional 11,080 shares during the period. Paloma Partners Management Co bought a new stake in shares of Inflarx in the fourth quarter worth about $526,000. RA Capital Management LLC grew its stake in shares of Inflarx by 6.0% in the fourth quarter. RA Capital Management LLC now owns 2,085,089 shares of the company’s stock worth $75,835,000 after purchasing an additional 117,241 shares during the last quarter. Bank of America Corp DE bought a new stake in shares of Inflarx in the fourth quarter worth about $657,000. Finally, Polar Capital LLP grew its stake in shares of Inflarx by 54.4% in the fourth quarter. Polar Capital LLP now owns 141,887 shares of the company’s stock worth $5,160,000 after purchasing an additional 50,000 shares during the last quarter. Institutional investors and hedge funds own 56.70% of the company’s stock.

Inflarx Company Profile

InflaRx N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing inhibitors using C5a technology primarily in the United States and Europe. Its C5a is an inflammatory mediator involved in the enhancement of a variety of autoimmune and other inflammatory diseases. The company’s lead product candidate is IFX-1, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that is in the Phase IIb clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; to treat ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and for the treatment of other chronic/autoimmune diseases.

Further Reading: Diversification in Your Portfolio

The Fly

Analyst Recommendations for Inflarx (NASDAQ:IFRX)



Receive News & Ratings for Inflarx Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Inflarx and related companies with MarketBeat.com’s FREE daily email newsletter.

Source link

Teen With North Fork Ties On New Single, ‘American Idol’ Audition

NORTH FORK, NY — Jackson Gillies, 19, is a young man with ties to the North Fork whose bright star continues to rise.

Gillies, a talented vocalist who has seen a steady ascent to stardom despite daunting physical challenges, won the Santa Barbara Teen Star USA competition in 2016 – and recently debuted his single and music video, “Miss Me Too.”

Gillies, who was previously known as Jackson Gillies Cocciolone, is soaring toward stardom. The debut of “Miss Me Too,” was a huge milestone in his life, he said. And, he also auditioned for the new, 17th season of “American Idol,” which begins airing on March 3 on ABC.

Reflecting on his new single, Gillies describes the song that already has North Fork friends raving on social media.

“I’m really really happy with it,” he said. “I started writing it sitting on my couch at home, thinking about my last relationship. I had broken up with this girl a few months ago, and it was a situation where there was no chance of getting back together. There were still some feelings there, so the song is sort of a question of ‘Do you still miss me? I know we can’t be together, but I want to know if the love is still there.'”

The song was recorded at Brotheryn Studio C in Ojai, CA, Gillies said, adding that his engineer, co-writer and co-producer was Jesse Siebenberg, and Ryan Slattery co-directed the video.

He and Siebenberg, he said, “met through mutual musician friends in Santa Barbara, and immediately hit it off. Jesse recently played Pedal Steel for a hefty number of tracks on the ‘Star Is Born’ soundtrack and co-wrote some of the songs with Bradley Cooper and Lukas Nelson. Needless to say, I’m a lucky guy to be working with him,” he said.

The song can be found on Gillies website here, or on YouTube.

“Since this is my first single, it’s my first inevitable sonic footprint on the world of music,” he said. “That footprint is relatively small now, but it will be interesting to look back at it in 10 years.”

Despite his young age, Gillies has scaled many hurdles, battling a number of health challenges; he was diagnosed at three years old with Type 1 diabetes and he has also battled Hidradenitis Suppurativa. HS is related to leaky gut, and toxins leaking out of the gut try to escape the body via lymph glands creating painful cysts, he said.

Nothing, however, has kept him from reaching for his own personal stars. “The mentality I keep when facing pain or struggle is that complaining won’t do anything for me. We’re all dealt with different hands and each one has its flaws; we have to power through if we can and reach for our goals. My advice is to remember it could always be worse, and always be thankful for the moment you’re in,” he said.

Perhaps one of Gillies’ most exciting moments came recently when he auditioned for “American Idol.”

Although he is unable to say much about the audition yet, he’s thrilled about the experience. “I do look forward to watching myself perform because I don’t remember a whole lot; I was just too excited. Look out for the Los Angeles auditions.”

His mom, Connie Gillies, urges: “Tune in to see if he gets the Gold Ticket!”

Gillies, who lives in Santa Barbara, CA and attends Santa Barbara City College, is fully immersed in music. “I’m currently writing as many songs as I can, and fueling my songs with experience. Honesty is the best tool you can use to reach other people. I’ll be releasing songs and music videos regularly, and hopefully won’t stop for a very long time,” he said.

Looking ahead, Gillies said his greatest dream for the future is to be a recording and touring artist, “and to touch people all over the world with my music. I want a life that’s exciting, but doesn’t necessarily have to be extreme every day. Meeting people and falling in love and getting heartbroken; that’s exciting. I never want to look back at the end of the day and think, ‘What if?'”

Her son, Connie said, recently received the Global Citizen Award from TVDSB for what he has done for the community, including a TEDx talk on Hidradenitis Suppurativa, his participation in the closed-loop artificial pancreas project trial research at Sansum Diabetes Research Institute, which led to FDA approval — he was one of 250 participants internationally, Connie said — and his efforts as co-creator and co-producer/performer at the “Teens Sing for Santa Barbara” Unity Shoppe Disaster Services benefit concert after the Thomas Fire and Montecito mudslide, which killed 23.

At the “Teens Sing for Santa Barbara” event, Gillies was one of three teens to conceive, produce and perform in the benefit concert, raising $70,000 for mudslide survivors; he was musical co-director with Kenny Loggins, who has encouraged his dream, and with whom he has worked.

“Kenny is a mentor to Jackson and he is so thankful for that,” his mother Connie said.

Although he is just 19, Gillies’ list of shining musical accomplishments is long: In 2018, at the One805 Kick Ash Bash fundraiser to honor and support Thomas Fire First Responders, Gillies performed with David Foster and the Janet Adderly Theatre Group, Kenny
Loggins, and The Sisterhood Band.

In 2017, he organized and performed at “Something That Matters,” an awareness concert for
Hidradenitis Suppurativa with Kenny Loggins, Tariqh Akoni, Randy Tico, Tom Lackner, Fausto
Cuevas, and LaNesha Latimer. Also in 2017, Gillies opened for and performed with Jim Messina and Band at the William Sansum Diabetes Research Center benefit in Santa Barbara.

And in 2016, the rising young star performed with Kenny Loggins, Michael McDonald, Christopher Cross, and others at the Concert Across America to End Gun Violence in Santa Barbara.

Gillies has always faced his challenges head-on, putting a face on Type 1 diabetes, and showing young people everywhere that the diagnosis does not have to keep them from reaching for their dreams.

He strives to become a successful songwriter and performer and to share his gift with the world. “I want to make music until the day I die,” he said.

In performing, Gillies has found the wings to soar above his physical challenges. “It is freeing to be able to perform and not feel constrained by my conditions. My physical struggles are out aside once I step on the stage,” he said.

His ties to the North Fork run deep: His grandparents, Jackson said, always summered on, and retired to, the North Fork; he’s got cousins, aunts and uncles in the area. He lived on the North Fork from sixth to ninth grade, and the memories are precious.

“I live in one of the most beautiful places in the world now. Santa Barbara is gorgeous but there is no place like the North Fork. There are stretches of beaches on Nassau Point that will always mean home to me,” he said.

For Connie Gillies, herself a talented local photographer and pianist, watching her son succeed is a gift beyond measure.

“Jackson is a special person and I love it when others pick up on it,” she said. Her son, she said, “is a great spirit. A comedian. An actor. A guitarist and singer and a wonderful friend and son. I hope whoever might read this gets a chance to meet him. Once you do, you won’t forget him.”

North Fork friends definitely haven’t forgotten Gillies, who touched scores with his talent and heart. “I’ve been watching this kid since he was performing on stage at Greenport High School’s ‘Guys & Dolls’ many years ago,” Greenport’s Rena Wilhelm wrote on social media after sharing her excitement about the single and music video— and her pride in Gillies for his hard work and dedication. “He’s an incredible talent but beyond that, he is an extraordinary individual. My heart feels like it is going to burst.”

For a full taste of his Gillies’ talent, check out his YouTube channel.

Get the North Fork newsletter

Subscribe

Source link

hidradenitis suppurativa excision

Find The Best Hidradenitis Solution Here: https://bit.ly/2GcgmlO hidradenitis suppurativa description hidradenitis suppurativa diabetes hidradenitis …

Source link